Trial Profile
An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 03 Mar 2024 Status changed from active, no longer recruiting to completed.
- 14 Jul 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 15 Jul 2022 Planned End Date changed from 1 Mar 2022 to 1 Dec 2022.